Everence Capital Management Inc. Invests $536,000 in ICU Medical, Inc. (NASDAQ:ICUI)

Everence Capital Management Inc. acquired a new position in ICU Medical, Inc. (NASDAQ:ICUI - Free Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 2,940 shares of the medical instruments supplier's stock, valued at approximately $536,000.

Other large investors have also modified their holdings of the company. Scout Investments Inc. increased its stake in shares of ICU Medical by 16.3% during the first quarter. Scout Investments Inc. now owns 51,819 shares of the medical instruments supplier's stock valued at $5,463,000 after buying an additional 7,272 shares during the period. Wakefield Asset Management LLLP purchased a new position in ICU Medical during the 1st quarter valued at about $989,000. Vanguard Group Inc. raised its holdings in shares of ICU Medical by 14.8% in the 4th quarter. Vanguard Group Inc. now owns 2,440,729 shares of the medical instruments supplier's stock valued at $243,438,000 after purchasing an additional 315,103 shares in the last quarter. SG Americas Securities LLC lifted its position in shares of ICU Medical by 441.7% in the 2nd quarter. SG Americas Securities LLC now owns 5,818 shares of the medical instruments supplier's stock worth $691,000 after purchasing an additional 4,744 shares during the period. Finally, Sei Investments Co. boosted its stake in shares of ICU Medical by 52.1% during the first quarter. Sei Investments Co. now owns 28,586 shares of the medical instruments supplier's stock valued at $3,068,000 after purchasing an additional 9,793 shares in the last quarter. Hedge funds and other institutional investors own 96.10% of the company's stock.

ICU Medical Stock Performance

Shares of ICUI traded up $0.84 during trading hours on Tuesday, hitting $179.77. The stock had a trading volume of 159,280 shares, compared to its average volume of 278,896. The firm has a 50-day moving average price of $170.71 and a 200 day moving average price of $133.02. ICU Medical, Inc. has a fifty-two week low of $78.28 and a fifty-two week high of $188.53. The firm has a market capitalization of $4.38 billion, a price-to-earnings ratio of -73.38 and a beta of 0.66. The company has a debt-to-equity ratio of 0.76, a quick ratio of 1.08 and a current ratio of 2.41.

ICU Medical (NASDAQ:ICUI - Get Free Report) last announced its earnings results on Wednesday, August 7th. The medical instruments supplier reported $1.56 earnings per share for the quarter, topping the consensus estimate of $1.00 by $0.56. The business had revenue of $596.50 million during the quarter, compared to the consensus estimate of $556.64 million. ICU Medical had a positive return on equity of 5.01% and a negative net margin of 3.07%. The business's quarterly revenue was up 8.6% on a year-over-year basis. During the same period in the prior year, the company posted $1.58 EPS. As a group, research analysts anticipate that ICU Medical, Inc. will post 3.76 EPS for the current year.

Insider Transactions at ICU Medical

In other ICU Medical news, CEO Vivek Jain sold 12,000 shares of ICU Medical stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $178.46, for a total transaction of $2,141,520.00. Following the sale, the chief executive officer now owns 104,593 shares of the company's stock, valued at $18,665,666.78. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In other news, CEO Vivek Jain sold 12,000 shares of the business's stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $178.46, for a total transaction of $2,141,520.00. Following the transaction, the chief executive officer now directly owns 104,593 shares in the company, valued at $18,665,666.78. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP Daniel Woolson sold 2,502 shares of the stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $163.22, for a total value of $408,376.44. Following the completion of the sale, the vice president now directly owns 13,107 shares of the company's stock, valued at approximately $2,139,324.54. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 40,552 shares of company stock valued at $6,679,322 over the last 90 days. Corporate insiders own 6.70% of the company's stock.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the company. Jefferies Financial Group began coverage on ICU Medical in a report on Monday, October 14th. They issued a "hold" rating and a $183.00 price target on the stock. Needham & Company LLC reiterated a "hold" rating on shares of ICU Medical in a research note on Thursday, October 10th. Raymond James increased their price objective on ICU Medical from $158.00 to $190.00 and gave the company an "outperform" rating in a report on Thursday, September 12th. StockNews.com upgraded ICU Medical from a "hold" rating to a "buy" rating in a research report on Thursday, September 12th. Finally, KeyCorp raised their price target on shares of ICU Medical from $147.00 to $198.00 and gave the stock an "overweight" rating in a research report on Tuesday, October 15th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, ICU Medical currently has a consensus rating of "Moderate Buy" and an average price target of $170.25.

ICU Medical Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.